Nov 6, 2025 · Cosentyx (secukinumab) is a biologic medication used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, enthesitis-related arthritis, hidradenitis suppurativa …

Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis COSENTYX was studied in one double-blind, placebo-controlled, event-driven, randomized trial in 86 pediatric patients aged 2 to < 18 …

Cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional …

Jan 29, 2025 · Overview: Cosentyx is used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. Common side effects include infection in the nose …

Dec 18, 2025 · Enthesitis-related arthritis (ERA) Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in …

New cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's …

1.5 Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older.

May 30, 2025 · Both Cosentyx UnoReady and Sensoready are FDA approved to treat: active enthesitis -related arthritis, in children ages 4 years and older moderate to severe hidradenitis …

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. …

May 16, 2025 · Secukinumab (Cosentyx) is an IL-17A blocker used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, enthesitis-related arthritis, hidradenitis suppurativa …